Skip to main content

Advertisement

SpringerLink
Log in

Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Introduction

DTC patients having detectable Tg and negative post-therapeutic 131I-WBS have to be investigated by different imaging techniques to detect metastases.

Purpose

Comparison of neck US, CT and [18F]-FDG PET scan.

Methods

In 49 DTC patients with biochemical disease, neck was examined by US, CT and [18F]-FDG PET. FNA was performed and Tg was determined by FNA-Tg in selected cases of suspicious lymph nodes. Thorax was examined by CT and PET. Serum Tg was measured on LT4 therapy (basal Tg) and after the stimulation with recombinant human TSH (peak Tg).

Results

A thyroid remnant was seen by US, CT and PET in eight patients; recurrences were seen by US, CT and PET in six, five and five patients, respectively. Two metastatic nodes were identified by US and CT but not by PET. Lung micronodules were detected by CT in 7/49 (14.3 %) patients and by FDG PET in three of them. Basal Tg ranged from 0.5–1,725 ng/ml while peak Tg ranged from 0.5 to 2,135 ng/ml: the distribution between positive and negative patients was similar. Bone scan was negative in all cases.

Conclusions

In DTC patients with detectable Tg and negative I-131 post-therapy WBS, imaging examination revealed remnant or metastases in 43 % of cases. Remnant and recurrences were equally detected by the three techniques; US was better than [18F]-FDG PET for lymph node metastases since this latter method can give false both positive and negative results; chest examination is best made by CT versus FDG PET due to its higher spatial resolution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Surveillance Epidemiology and End-Results Cancer Registries Program 2013: http://seer.cancer.gov/

  2. Pacini F, Pinchera A, Giani C, Grasso L, Baschieri L (1980) Serum thyroglobulin concentration and 131-I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol 13:107–110

    Article  CAS  Google Scholar 

  3. Pacini F, Lippi F, Formica N et al (1987) Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28(12):1888–1889

    PubMed  CAS  Google Scholar 

  4. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J (1995) Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488–1492

    PubMed  CAS  Google Scholar 

  5. Pacini F, Castagna MG (2012) New insight in the follow-up strategies of differentiated thyroid cancer. J Endocrinol Invest 35(6 Suppl):36–39

    PubMed  CAS  Google Scholar 

  6. Elisei R, Pinchera A (2012) Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol 8(8):466–475

    Article  PubMed  CAS  Google Scholar 

  7. Pacini F, Agate L, Elisei R et al (2001) Outcome of differentiated thyroid cancer with detectable serum thyroglobulin and negative diagnostic 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients. J Clin Endocrinol Metab 86:4092–4097

    Article  PubMed  CAS  Google Scholar 

  8. Pacini F, Cetani F, Miccoli P et al (1994) Outcome of 309 patients with metastatic thyroid carcinoma. World J Surg 18:600–604

    Article  PubMed  CAS  Google Scholar 

  9. Arturi F, Russo D, Schlumberger M, Du Villard JA, Caillou B, Vigneri P (1998) Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 83:2193–2196

    Google Scholar 

  10. Westbury C, Vini L, Fisher C, Harmer C (2000) Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid 10:171–176

    Article  PubMed  CAS  Google Scholar 

  11. Petrich T, Widjaij A, Musholt TJ et al (2001) Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side effects and influence of age. Eur J Nucl Med 28:203–208

    Article  PubMed  CAS  Google Scholar 

  12. Ceccarelli C, Bianchi F, Trippi D et al (2004) Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan. J Endocrinol Invest 27:866–869

    Article  PubMed  CAS  Google Scholar 

  13. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N (2002) Relationship between tumour burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 12:707–711

    Article  PubMed  CAS  Google Scholar 

  14. Grunwald F, Kalicke T, Feine U et al (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547–1552

    Article  PubMed  CAS  Google Scholar 

  15. Schluter B, Bohuslaviziki KH, Beyer W et al (2001) Impact of FDG-PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42:71–76

    PubMed  CAS  Google Scholar 

  16. Menzel C, Zaplatnikov K, Diehl M et al (2004) The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun 25:239–243

    Article  PubMed  CAS  Google Scholar 

  17. Filetti S, Damante G, Foti D (1987) Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinology 120:2576–2581

    Article  PubMed  CAS  Google Scholar 

  18. Moog F, Linke R, Manthey N et al (2000) Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41:1989–1995

    PubMed  CAS  Google Scholar 

  19. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW (2007) The role of PET in follow-up pf patients treated for differentiated epithelial thyroid cancers. Surgery 142:952–958

    Article  Google Scholar 

  20. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH (2002) Influence of rhTSH on [(18)F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 29:641–647

    Article  PubMed  CAS  Google Scholar 

  21. Wang W, Macapinlac H, Larson SM et al (1999) [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291–2302

    Article  PubMed  CAS  Google Scholar 

  22. Pacini F, Molinaro E, Castagna MG et al (2003) Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitività in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668–3673

    Article  PubMed  CAS  Google Scholar 

  23. Grant CS, Thompson GB, Farley DR, Richards ML, Mullan BP, Hay ID (2008) The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma. World J Surg 32:708–715

    Article  PubMed  Google Scholar 

  24. Yeung HW, Grewal RK, Gonen M, Schoder H, Larson SM (2003) Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 44:1789–1796

    PubMed  Google Scholar 

  25. Aquino SL, Kuester LB, Muse VV, Halpern EF, Fischman AJ (2006) Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT. Eur J Nucl Med Mol Imaging 33:692–696

    Article  PubMed  Google Scholar 

  26. Palmedo H, Bucerius J, Joe A et al (2006) Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47:616–624

    PubMed  Google Scholar 

  27. Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL (2007) Combined (18F)Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol 15:286–292

    Article  PubMed  Google Scholar 

  28. Shammas A, Degirmenci B, Mountz JM et al (2007) F-18-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48:221–226

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Supported in part by Grants from Associazione Italiana Ricerca sul Cancro (AIRC).

Conflict of interest

The authors have nothing to disclose.

Author information

Authors and Affiliations

  1. Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 56127, Pisa, Italy

    Laura Agate, Francesca Bianchi, V. Bottici, F. Brozzi, P. Santini, E. Molinaro, P. Vitti, R. Elisei & C. Ceccarelli

  2. Fondazione CNR/Regione Toscana “G.Monasterio”, Pisa, Italy

    A. Giorgetti

  3. Department of Radiology, University of Pisa Medical School and Hospital, Pisa, Italy

    P. Sbragia

Authors
  1. Laura Agate
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Bianchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Giorgetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Sbragia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Bottici
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Brozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Santini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Molinaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Vitti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. Elisei
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C. Ceccarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura Agate.

Additional information

L. Agate and F. Bianchi equally contributed to this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Agate, L., Bianchi, F., Giorgetti, A. et al. Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels. J Endocrinol Invest 37, 967–972 (2014). https://doi.org/10.1007/s40618-014-0134-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-014-0134-1

Keywords

Search

Navigation